Immutep Reports Strong Financial Position with A$159M Cash Balance, Advances Clinical Programs
Australian biotechnology company Immutep continues to demonstrate financial stability while advancing its clinical development programs for efti and IMP761, according to its latest quarterly financial report.
The company reported a strong financial position with approximately A$159.26 million in total cash and term deposits as of December 31, 2023. This substantial balance comprises A$73.89 million in cash and cash equivalents, complemented by A$85.37 million in bank term deposits with maturities between 3 and 12 months. This financial cushion is expected to support operations through the end of calendar year 2026.
Research and Development Progress
Research and development activities saw significant expansion during the quarter, with expenditures reaching A$16.2 million, marking a notable increase from A$9.5 million in Q1 FY25. This surge in R&D investment primarily reflects the intensification of clinical trial activities, particularly the initiation of the phase III TACTI-004 clinical trial.
Operational Efficiency
The company demonstrated careful management of operational expenses, with general and administrative costs decreasing to A$566,000 in Q2, down from A$961,000 in the previous quarter. Staff-related expenses also showed modest reduction, dropping to A$2.5 million from A$2.8 million in Q1 FY25.
Financial Performance Metrics
Customer receipts for the quarter stood at A$8,000, while total net cash outflows from operating activities amounted to A$19 million, an increase from A$8.6 million in Q1 FY25, primarily attributed to the expanded clinical trial activities. Payments to related parties, including Non-Executive Directors' fees and Executive Directors' remuneration, totaled A$344,000.
The company's strategic allocation of resources, particularly the significant investment in clinical development while maintaining efficient operational costs, positions Immutep favorably for advancing its immunotherapy pipeline through key development milestones over the coming years.